ReviewTherapeutic advances in medical oncology2026
Immunogenicity remodeling in hepatocellular carcinoma: mechanisms and translational strategies.
Review in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) continues to pose a significant global health challenge. In recent years, immunotherapy has emerged as a critical component of HCC treatment, demonstrating encouraging outcomes in a subset of patients. Nevertheless, the overall response rate to immune checkpoint inhibitors (ICIs) remains modest. Deficient immunogenicity and the consequent failure to adequately activate antitumor immunity are widely regarded as central constraints on immunotherapy efficacy. Unlike previous reviews focusing on immune escape or clinical outcomes, this review centers on tumor immunogenicity as the key determinant of immunotherapy response. We systematically summarize the major mechanisms regulating HCC immunogenicity and outline current strategies to enhance and remodel it. By conceptualizing immunogenicity as the principal determinant of immunotherapy efficacy, we propose a unified framework centered on immunogenicity that integrates intrinsic tumor characteristics, microenvironmental regulation, and diverse therapeutic interventions. Within this framework, we highlight representative immunogenicity‑enhancing strategies, including epigenetic restoration of antigen presentation capacity, induction of immunogenic cell death through local or systemic therapies, and vaccine‑based approaches aimed at amplifying antitumor immunity. Collectively, this review offers a systematic and coherent perspective on immune tolerance in HCC through the lens of immunogenicity remodeling, thereby providing a conceptual foundation for the rational design of future immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.